Bringing the very best science and medicine to our best equine friends

NEWS

Kindred Biosciences Announces First Quarter 2016 Financial Results

San Francisco, CA (May 5, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2016 and provided updates on its programs. “We successfully advanced our lead product candidates in the first quarter. We look forward to reporting topline results for KIND-010, a transdermal gel for the management of weight loss in cats, by mid-year, as planned. Additionally, preparations for the commercial launch of Zimeta for fever in horses are on track, positioning KindredBio for the expected revenue generation by the …

Continue Reading

Kindred Biosciences to Announce First Quarter 2016 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday, May 5, 2016 San Francisco, CA (April 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2016 financial results on May 5, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) …

Continue Reading

Kindred Biosciences Elects Herbert D. Montgomery to Join Its Board of Directors

Highly Experienced Finance Executive to Join KindredBio’s Board San Francisco, CA (April 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mr. Herbert Montgomery will be joining the Company’s Board of Directors.  Mr. Montgomery will serve as the Chairman of the Company’s Audit Committee. Mr. Montgomery has extensive experience in finance, including having served as CFO of several public companies, and having taken three companies public.  Most recently, he was Vice Chairman of the Board and Executive Officer of Lightpost Holdings, LLC. Prior to that, Mr. Montgomery …

Continue Reading

PRESS RELEASE – Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA

San Francisco, CA (March 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016. In the target animal safety study, Zimeta, was well tolerated with no clinically-significant changes when compared to control horses (placebo ...
Continue Reading

Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA

San Francisco, CA (March 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016. In the target animal safety study, Zimeta, was well tolerated with no clinically-significant changes when compared to control horses (placebo …

Continue Reading

Kindred Biosciences Announces Fourth Quarter and Year-End 2015 Financial Results

San Francisco, CA (March 2, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2015. “We are very pleased with the progress on Zimeta™, our lead product candidate, and look forward to our first product approval and launch,” stated Richard Chin, M.D., President and CEO of KindredBio. “We are also pleased to report that the strong pipeline of additional products, including KIND-010 for management of weight in cats and feline epo for anemia in cats, are also …

Continue Reading

Kindred Biosciences to Announce Fourth Quarter and Year-End 2015 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 2, 2016 San Francisco, CA (February 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2015 financial results on March 2, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, …

Continue Reading